Foghorn Stock Plunges After a Patient’s Death. Analysts Say It’s Still a Buy.
Text size The pause on Foghorn's study is only temporary, analysts say. Bogdan Hoda/Dreamstime Foghorn Therapeutics ...
Read moreText size The pause on Foghorn's study is only temporary, analysts say. Bogdan Hoda/Dreamstime Foghorn Therapeutics ...
Read moreUpdated Dec. 13, 2021 8:21 am ET Stock futures are up after the S&P 500 hit ...
Read more© 2022 TheDailyStock.News